TY - JOUR
T1 - Bioprinting technologies for disease modeling
AU - Memic, Adnan
AU - Navaei, Ali
AU - Mirani, Bahram
AU - Cordova, Julio Alvin Vacacela
AU - Aldhahri, Musab
AU - Dolatshahi-Pirouz, Alireza
AU - Akbari, Mohsen
AU - Nikkhah, Mehdi
N1 - Funding Information:
MN would like to acknowledge National Science Foundation (Award 1510700 and CAREER Award CBET 1653193). AM would like to acknowledge the National Plan for Science, Technology and Innovation (MAARIFAH)—King Abdulaziz City for Science and Technology—the Kingdom of Saudi Arabia—award number (12-MED3096-3). The authors also, acknowledge the Science and Technology Unit, King Abdulaziz University.
Publisher Copyright:
© 2017, Springer Science+Business Media Dordrecht.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - There is a great need for the development of biomimetic human tissue models that allow elucidation of the pathophysiological conditions involved in disease initiation and progression. Conventional two-dimensional (2D) in vitro assays and animal models have been unable to fully recapitulate the critical characteristics of human physiology. Alternatively, three-dimensional (3D) tissue models are often developed in a low-throughput manner and lack crucial native-like architecture. The recent emergence of bioprinting technologies has enabled creating 3D tissue models that address the critical challenges of conventional in vitro assays through the development of custom bioinks and patient derived cells coupled with well-defined arrangements of biomaterials. Here, we provide an overview on the technological aspects of 3D bioprinting technique and discuss how the development of bioprinted tissue models have propelled our understanding of diseases’ characteristics (i.e. initiation and progression). The future perspectives on the use of bioprinted 3D tissue models for drug discovery application are also highlighted.
AB - There is a great need for the development of biomimetic human tissue models that allow elucidation of the pathophysiological conditions involved in disease initiation and progression. Conventional two-dimensional (2D) in vitro assays and animal models have been unable to fully recapitulate the critical characteristics of human physiology. Alternatively, three-dimensional (3D) tissue models are often developed in a low-throughput manner and lack crucial native-like architecture. The recent emergence of bioprinting technologies has enabled creating 3D tissue models that address the critical challenges of conventional in vitro assays through the development of custom bioinks and patient derived cells coupled with well-defined arrangements of biomaterials. Here, we provide an overview on the technological aspects of 3D bioprinting technique and discuss how the development of bioprinted tissue models have propelled our understanding of diseases’ characteristics (i.e. initiation and progression). The future perspectives on the use of bioprinted 3D tissue models for drug discovery application are also highlighted.
KW - 3D bioprinting
KW - Disease microenvironment
KW - Disease modeling
KW - In vitro tissue models
UR - http://www.scopus.com/inward/record.url?scp=85019670152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019670152&partnerID=8YFLogxK
U2 - 10.1007/s10529-017-2360-z
DO - 10.1007/s10529-017-2360-z
M3 - Review article
C2 - 28550360
AN - SCOPUS:85019670152
SN - 0141-5492
VL - 39
SP - 1279
EP - 1290
JO - Biotechnology Letters
JF - Biotechnology Letters
IS - 9
ER -